Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2018-12-02 Board/Management Inform…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Anders Lönner, chairman of the Board Karo Pharma AB, has suddenly passed away
Board/Management Information Classification · 98% confidence The document is a press release announcing the sudden passing of the Chairman of the Board, Anders Lönner, and the appointment of an Acting Chairman. This constitutes a significant change in senior management/board composition. Based on the provided definitions, the most appropriate category is 'Board/Management Information' (MANG). It is not an earnings release (ER), a formal regulatory report (like 10-K or IR), or a director's dealing (DIRS), but specifically addresses a change in board leadership.
2018-12-02 English
Karo Pharmas Styrelseordförande Anders Lönner har hastigt avlidit
Board/Management Information Classification · 98% confidence The document is a formal announcement dated December 2, 2018, regarding the sudden death of the Chairman of the Board, Anders Lönner. It details his career achievements and names the interim replacement. The text explicitly states: "Denna information är sådan information som Karo Pharma AB är skyldig att offentliggöra enligt EUs marknadsmissbruksförordning." This indicates a mandatory regulatory disclosure concerning a significant internal change. This type of announcement, detailing a change in senior management or board composition, directly corresponds to the definition of Board/Management Information (MANG). It is not an earnings release (ER), a general regulatory filing (RNS), or a proxy statement (PSI).
2018-12-02 Swedish
MARKNADSRÄTTIGHETERNA FÖR VIRUSEPTIN® UTÖKAS TILL ATT OMFATTA DANMARK
Regulatory Filings Classification · 95% confidence The document is a short press release (1005 characters) announcing an expansion of market rights for a product (Viruseptin®) into Denmark, completing Nordic coverage. It contains key highlights, contact information, and a boilerplate 'About' section. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific, non-financial corporate announcement (market expansion/licensing news) that doesn't fit the other specific categories (like DIRS, DIV, CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/corporate news announcements not covered elsewhere. It is too specific to be a general LTR or too brief/non-financial to be an ER or IR.
2018-11-16 Swedish
MARKETING TERRITORY FOR VIRUSEPTIN® EXTENDED TO INCLUDE DENMARK
Regulatory Filings Classification · 95% confidence The document is very short (1075 characters) and appears to be a press release announcing a business development: the extension of marketing territory for a product (Viruseptin®) to include Denmark. It contains key highlights, contact information, and a boilerplate 'About' section, concluding with a statement about the information submission time. This structure strongly suggests an initial announcement of news rather than a comprehensive report (like 10-K or IR). Since it is a specific business update that doesn't fit the definitions for Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), it falls best under the general Regulatory Filings/Announcements category, which is RNS, as it is a general regulatory announcement/press release.
2018-11-16 English
Anders Lönner and Per-Anders Johansson have irrevocably undertaken to accept the public cash offer announced by EQT VIII, through Karo Intressenter AB, on October 29, 2018
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated November 9, 2018, announcing that two key directors (Anders Lönner and Per-Anders Johansson) have irrevocably undertaken to accept a public cash offer for their shares in Karo Pharma, made by EQT VIII. This announcement concerns significant transactions involving the shares held by company insiders/directors, specifically related to a takeover bid (M&A activity). While it relates to a takeover (TAR), the core focus is the commitment of directors regarding their shareholdings in response to the offer. However, the most direct classification for announcements detailing personal share transactions by directors, especially in the context of a takeover or otherwise, is Director's Dealing (DIRS). Since the document explicitly details undertakings by directors regarding their shares, DIRS is a strong candidate. Given the context is a public cash offer (takeover), TAR (M&A Activity) is also highly relevant. Since the document is a press release announcing a specific event (director undertakings related to an offer) rather than the full details of the M&A transaction itself or a standard insider trade report, and it is short (4274 chars), it could potentially be RNS if it doesn't fit perfectly. However, the content is highly specific to director actions concerning share ownership during a takeover. Since the primary action described is the director's commitment to sell their shares (a form of dealing/transaction), and it is an announcement, I will prioritize the M&A context as the driving event. The document details the background of the public cash offer and the subsequent undertakings by directors to accept it. This falls squarely under M&A Activity (TAR) as it is a direct consequence and update related to the takeover bid announced on Oct 29, 2018. It is not a standard Director's Dealing report (DIRS) which usually focuses on routine trades, but rather a strategic move tied to the takeover.
2018-11-09 English
Anders Lönner och Per-Anders Johansson har oåterkalleligen åtagit sig att acceptera det offentliga kontanterbjudandet som EQT VIII, genom Karo Intressenter AB, offentliggjorde den 29 oktober 2018
Major Shareholding Notification Classification · 99% confidence The document text discusses a public cash offer (kontanterbjudande) made by EQT VIII through Karo Intressenter AB for shares in Karo Pharma Aktiebolag. It specifically details that key directors (Anders Lönner and Per-Anders Johansson) have irrevocably committed (åtagit sig att acceptera) to tender their shares. This content relates directly to a takeover bid or merger proposal involving the company's shares and ownership structure. This aligns best with the definition for M&A Activity (TAR). It is not a general earnings release (ER), a full annual report (10-K), or a simple director's dealing report (DIRS), as it concerns a formal takeover bid recommendation and acceptance commitments.
2018-11-09 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.